Tiziana Life Sciences plc

General Information
Business:

(Note: “Our ordinary shares trade on AIM, a market of the London Stock Exchange plc, or London Stock Exchange, under the symbol “TILS.” On September 21, 2018, the last reported sale price of our ordinary shares was £1.12 per share (equivalent to $10.25 per ADS based on an exchange rate of £1.00 to $1.3084)”)

We are a biotechnology company that is focused on the discovery and development of novel molecules and related diagnostics to treat high unmet medical needs in oncology and immunology. Our lead product candidate in immunology is Foralumab (TZLS-401), which we believe is the only fully human anti-CD3 monoclonal antibody, or mAb, in clinical development. MAbs represent a single pure antibody produced by single clones and are an important class of human therapeutics for treating cancers and autoimmune diseases.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 14
Founded: 1998
Contact Information
Address 3rd Floor, 11-12 St James’s Square, London SW1 4LB United Kingdo
Phone Number +44 20 7495 2379
Web Address http://www.tizianalifesciences.com
View Prospectus: Tiziana Life Sciences plc
Financial Information
Market Cap
Revenues $0 mil (last 12 months)
Net Income $-9.3 mil (last 12 months)
IPO Profile
Symbol TLSA
Exchange NASDAQ
Shares (millions): 1.6
Price range $10.25 - $10.25
Est. $ Volume $161.0 mil
Manager / Joint Managers Laidlaw & Company (UK) Ltd.
CO-Managers -
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change